Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Diabetes Care
|
April 9, 2013
Low-carbohydrate diet for the treatment of gestational diabetes mellitus: a randomized controlled trial
Cristina Moreno-Castilla, Marta Hernandez, Merce Bergua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
JCO Precision Oncology
|
September 10, 2021
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
Aditya Bardia, Fei Su, Nadia Solovieff, et al.
The New England Journal of Medicine
|
June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Nordic Journal of Psychiatry
|
August 30, 2021
Treatment of difficult-to-treat depression - clinical guideline for selected interventions
Stine Bjerrum Moeller, Krzysztof Gbyl, Carsten Hjorthøj, et al.
Blood Cancer Journal
|
April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
Shaji Kumar, Katja C Weisel, Paul Spin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hans C Lee, Naresh Bumma, Joshua Richter, et al.
Science Translational Medicine
|
December 13, 2023
A therapeutic strategy to target distinct sources of IgE and durably reverse allergy
Andre Limnander, Navneet Kaur, Seblewongel Asrat, et al.
The New England Journal of Medicine
|
December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Diabetes Care
|
April 9, 2013
Low-carbohydrate diet for the treatment of gestational diabetes mellitus: a randomized controlled trial
Cristina Moreno-Castilla, Marta Hernandez, Merce Bergua, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
JCO Precision Oncology
|
September 10, 2021
Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
Aditya Bardia, Fei Su, Nadia Solovieff, et al.
The New England Journal of Medicine
|
June 6, 2019
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im, Yen-Shen Lu, Aditya Bardia, et al.
Nordic Journal of Psychiatry
|
August 30, 2021
Treatment of difficult-to-treat depression - clinical guideline for selected interventions
Stine Bjerrum Moeller, Krzysztof Gbyl, Carsten Hjorthøj, et al.
Blood Cancer Journal
|
April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
Shaji Kumar, Katja C Weisel, Paul Spin, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 1, 2025
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hans C Lee, Naresh Bumma, Joshua Richter, et al.
Science Translational Medicine
|
December 13, 2023
A therapeutic strategy to target distinct sources of IgE and durably reverse allergy
Andre Limnander, Navneet Kaur, Seblewongel Asrat, et al.
The New England Journal of Medicine
|
December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Page
of 5